DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ceprotin (Protein C) - Published Studies

 
 



Ceprotin Related Published Studies

Well-designed clinical trials related to Ceprotin (Protein C)

Combination of activated protein C and topical negative pressure rapidly regenerates granulation tissue over exposed bone to heal recalcitrant orthopedic wounds. [2011.09]

A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. [2011.08]

Recombinant surfactant protein C-based surfactant for patients with severe direct lung injury. [2011.04.15]

Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism. [2011]

Combination of activated protein C and topical negative pressure rapidly regenerates granulation tissue over exposed bone to heal recalcitrant orthopedic wounds. [2011]

Protein C and protein S changes in GH-deficient adults on r-HGH replacement therapy: correlations with PAI-1 and t-PA plasma levels. [2010.12]

Fat-free mass change after nutritional rehabilitation in weight losing COPD: role of insulin, C-reactive protein and tissue hypoxia. [2010.02.18]

Activated protein C in severe acute pancreatitis without sepsis? Not just yet ... [2010]

Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated). [2010]

Recombinant human activated protein C attenuates cardiovascular and microcirculatory dysfunction in acute lung injury and septic shock. [2010]

Effects of recombinant human activated protein C on the fibrinolytic system of patients undergoing conventional or tight glycemic control. [2009.07]

Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies. [2009]

Randomized clinical trial of activated protein C for the treatment of acute lung injury. [2008.09.15]

Current role of activated protein C therapy for severe sepsis and septic shock. [2008.09]

Protein C -1641A/-1654C haplotype is associated with organ dysfunction and the fatal outcome of severe sepsis in Chinese Han population. [2008.04]

Human recombinant activated protein C for severe sepsis. [2008.01.23]

[Effect of TCM treatment for dissolving phlegm and dispelling stasis on plasma protein and thrombomodulin in patients with acute cerebral infarction] [2007.11]

Human recombinant activated protein C for severe sepsis. [2007.07.18]

Effects of diet with or without exercise on leptin and anticoagulation proteins levels in obesity. [2007.07]

Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system. [2007.06]

The effect of activated protein C on plasma cytokine levels in a porcine model of acute endotoxemia. [2007.06]

Cost-effectiveness of activated protein C in real-life clinical practice. [2007]

Well-designed clinical trials possibly related to Ceprotin (Protein C)

Effect of a multispecies probiotic on inflammatory markers in critically ill patients: A randomized, double-blind, placebo-controlled trial. [2014]

Effects of methylprednisolone infusion on markers of inflammation, coagulation, and angiogenesis in early acute respiratory distress syndrome. [2011.10.06]

Metabolic profile of a continuous versus a cyclic low-dose combined oral contraceptive after one year of use. [2011.04]

Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17beta-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. [2011.03]

Adjunctive corticosteroid therapy in pediatric severe sepsis: observations from the RESOLVE study. [2011.01]

Adjunctive corticosteroid therapy in pediatric severe sepsis: observations from the RESOLVE study. [2011]

Green tea improves metabolic biomarkers, not weight or body composition: a pilot study in overweight breast cancer survivors. [2010.12]

Prowess-shock trial: a protocol overview and perspectives. [2010.09]

The association between BMI and plasma cytokine levels in patients with acute lung injury. [2010.09]

Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. [2010.08]

An open-label, comparative study of the effects of a dose-reduced oral contraceptive containing 0.02 mg ethinylestradiol/2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables. [2010.05]

Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. [2010.02]

Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate. [2009.12]

[18F]fluorodeoxyglucose positron emission tomography for lung antiinflammatory response evaluation. [2009.09.15]

Biomarkers of thrombosis, fibrinolysis, and inflammation in patients with severe sepsis due to community-acquired pneumonia with and without Streptococcus pneumoniae. [2009.08]

Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis. [2009.07]

Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock. [2009.07]

The impact of selective and non-selective non-steroid anti-inflammatory drugs on secondary hemostasis in healthy volunteers. [2009.06]

Alterations in the human lung proteome with lipopolysaccharide. [2009.05.11]

Strategies to increase vegetable or reduce energy and fat intake induce weight loss in adults. [2009.05]

Venous thromboembolism in critically ill patients. Observations from a randomized trial in sepsis. [2009.01]

The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. [2009.01]

Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study. [2009]

Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis. [2008.12]

Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters. [2008.11]

The current management of septic shock. [2008.10]

Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone. [2008.08]

[Clinical research on Gancao Fuzi decoction in treating osteoarthritis of knee joint] [2008.07]

Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. [2008.02]

Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables. [2008.02]

Effects of isoflavones on the coagulation and fibrinolytic system of postmenopausal women. [2008.02]

A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: Comparison with a controlled clinical trial. [2008.01]

Anticoagulant therapy in acute lung injury: a useful tool without proper operating instruction? [2008]

My brother has severe sepsis Should he receive Xigris(R)? [2007.12]

Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. [2007.09.25]

Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). [2007.09.01]

Drotrecogin alfa (activated) in the treatment of severe sepsis. [2007.09]

Major coagulation disturbances during fractionated plasma separation and adsorption. [2007.09]

[Laparoscopic cholecystectomy for acute cholecystitis] [2007.08]

Surfactant function and composition in premature infants treated with inhaled nitric oxide. [2007.08]

Warfarin cessation before cardiopulmonary bypass: lessons learned from a randomized controlled trial of oral vitamin K. [2007.07]

Patients with ARDS show improvement but not normalisation of alveolar surface activity with surfactant treatment: putative role of neutral lipids. [2007.07]

Successful kidney transplantation does not reverse the coagulopathy in patients with chronic renal failure on either hemo or peritoneal dialysis. [2007.06]

ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: One-year safety and efficacy evaluation. [2007.06]

Effect of depomedroxyprogesterone acetate on coagulation parameter: a pilot study. [2007.06]

Haemostatic activation in post-menopausal women taking low-dose hormone therapy: Less effect with transdermal administration? [2007.04]

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. [2007.03.10]

Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. [2007.02.06]

Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis. [2007.01]

Rapid activation of haemostasis after hormonal emergency contraception. [2007.01]

Salmeterol enhances pulmonary fibrinolysis in healthy volunteers. [2007.01]

Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. [2007.01]

Relationship between thrombophilic disorders and type of severe early-onset hypertensive disorder of pregnancy. [2007]

Effects of Eicosapentaenoic and Docosahexaenoic n-3 Fatty Acids From Fish Oil and Preferential Cox-2 Inhibition on Systemic Syndromes in Patients With Advanced Lung Cancer. [2007]

RESOLVE-ing sepsis in children--not yet! [2007]

Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis. [2007]

Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a multicenter, randomized, double-blind study. [2007]

Other research related to Ceprotin (Protein C)

Recombinant human activated protein C in the treatment of acute respiratory distress syndrome: a randomized clinical trial. [2014]

Activated protein C attenuates pulmonary coagulopathy in patients with acute respiratory distress syndrome. [2013]

Circulating nucleosomes and severity of illness in children suffering from meningococcal sepsis treated with protein C. [2012]

Recombinant human activated protein C as a disease modifier in severe acute pancreatitis: systematic review of current evidence. [2012]

Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy. [2012]

Activated protein C in patients with septic shock: a consecutive case series. [2011.11.27]

Combined Recombinant Human Activated Protein C and Ceftazidime Prevent the Onset of ARDS in Severe Sepsis. [2011.11.15]

Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice. [2011.09.15]

Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT. [2011.09.08]

Long-term intrathecal infusion of outer surface protein C from Borrelia burgdorferi causes axonal damage. [2011.09]

The influence of carbohydrate-protein co-ingestion following endurance exercise on myofibrillar and mitochondrial protein synthesis. [2011.08.15]

Successful treatment of severe sepsis with recombinant activated protein C during the third trimester of pregnancy. [2011.08]

Surfactant protein C is an essential constituent for mucosal adjuvanticity of Surfacten, acting as an antigen delivery vehicle and inducing both local and systemic immunity. [2011.07.26]

Activated protein C inhalation: a novel therapeutic strategy for acute lung injury. [2011.06]

Long-term subcutaneous protein C replacement in neonatal severe protein C deficiency. [2011.05]

Zymogen Protein C to prevent clotting without bleeding during invasive medical procedures. [2011]

A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. [2011]

Analysis of cardiac myosin binding protein-C phosphorylation in human heart muscle. [2010.09.17]

Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. [2010.07.07]

Activated protein C attenuates cardiopulmonary bypass-induced acute lung injury through the regulation of neutrophil activation. [2010.07.03]

Prevalence of serious bleeding events and intracranial hemorrhage in patients receiving activated protein C: a systematic review and meta-analysis. [2010.07]

Treatment of the critically ill patient with protein C: is it worth the cost? [2010.06]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017